Recruiting
Phase 2

Aglatimagene Besadenovec & Valacyclovir

Sponsor:

Candel Therapeutics, Inc.

Code:

NCT07332000

Conditions

Prostate Cancer Patients Treated by Radiotherapy

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

aglatimagene besadenovec + valacyclovir

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-19. This information was provided to ClinicalTrials.gov by Candel Therapeutics, Inc. on 2026-01-12.